Rubraca (rucaparib)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Rubraca (rucaparib)

How to buy Rubraca: You can order Rubraca (rucaparib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Clovis Oncology Inc.
Disease Ovarian Cancer
Indication Deleterious BRCA mutation associated with advanced ovarian cancer
Mode of Action PARP inhibitor
Approval Status FDA approved (USA)
Strength 300 mg, 200 mg

Who is rucaparib for?

Rubraca (rucaparib) is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies [1]. Patients should be selected for therapy based on the FDA-approved FoundationFocus CDxBRCA test (Foundation Medicine Inc.) [2][1].

Recommended dose

Complete information about Rubraca (rucaparib) dosage and administration can be found here [1].
The standard dosage is:
  • 600 mg orally twice daily.
Patients should be monitored for hematologic toxicity at baseline and monthly thereafter, and use of Rubraca (rucaparib) should be discontinued if myelodysplastic syndrome (MDS) / acute myeloid leukemia (AML) is confirmed [1].
Consult your treating doctor for personalised dosing.

What is rucaparib and how does it work?

Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies [1]. Approximately 15 to 20 % of patients with ovarian cancer have a BRCA gene mutation. BRCA genes are involved with repairing damaged DNA and normally work to prevent tumour development. However, mutations of these genes may lead to certain cancers, including ovarian cancers. Rubraca (rucaparib) is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the cancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a slowdown or stoppage of tumour growth [3].

What is rucaparib's approval status?

Rubraca (rucaparib) was approved by:
  • FDA (USA) on December 19, 2016
for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies [1].
The approval was based on a study involving 106 adults with BRCA-mutated advanced ovarian cancer who had been treated with two or more chemotherapy regimens. BRCA gene mutations were confirmed in 96 % of tested trial participants with available tumour tissue using the FDA approved diagnostic FoundationFocus CDxBRCA [2]. Of the participants who received Rubraca (rucaparib) in the trials, 54 % experienced complete or partial shrinkage of their tumours lasting a median of 9.2 months [4].
The safety of Rubraca (rucaparib) was evaluated in 377 patients with advanced ovarian cancer. The most common adverse reactions (greater than or equal to 20 %) experienced by patients were nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea. MSD/AML was reported in 2 out of 377 (0.5 %) patients with ovarian cancer. In addition, AML was reported in 2 (<1 %) patients with ovarian cancer enrolled in a blinded, randomised trial evaluating rucaparib versus placebo [4].
The most common adverse reactions were nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia (distortion of the sense of taste), constipation, decreased appetite, diarrhea, thrombocytopenia (deficiency of platelets in the blood), and dyspnea (difficult breathing)Β [1].
On October 12, 2012, the European EMA granted orphan designation to Clovis Oncology UK Limited, United Kingdom, for rucaparib for the treatment of ovarian cancer [5].
[1] Summary of Product Characteristics [FDA]: Rubraca (rucaparib), Clovis Oncology Inc., Dec. 2016.
[2] Foundation Medicine. Foundation Focus CDXBRCA. Cited on 30/01/2017.
[3] FDA News Release: FDA grants accelerated approval to new treatment for advanced ovarian cancer, 19/12/2016.
[4] FDA. Approved Drugs: Rucaparib, 19/12/2016.
[5] EMA. Rare disease designations: EU/3/12/1049, 16/11/2012, cited on 30/01/2017.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

β˜… β˜… β˜… β˜… β˜…

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

β€” Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

β€” Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

β€” Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

β€” Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

β€” Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

β€” Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

β€” Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

β€” Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

β€” Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

β€” Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.